voyager therapeutics
-
Novartis Returns to Voyager Therapeutics to Reach New Gene Therapy Destinations
Novartis is paying Voyager Therapeutics $100 million up front to collaborate on gene therapies for Huntington’s disease and spinal muscular atrophy. The deal builds on a relationship the companies started in 2022.
-
Neurocrine Commits $175M to Voyager in New Neuro Gene Therapy Alliance
Neurocrine Biosciences is paying $175 million up front for rights to a preclinical Voyager Therapeutics gene therapy that could put the biotech in competition with Eli Lilly among other companies. Voyager could earn up to $4.2 billion in milestone payments.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Novartis turns to Voyager Therapeutics to get gene therapies into the brain
Novartis is paying Voyager Therapeutics $54 million up front to begin a partnership focused on the discovery of capsids for central nervous system disorder gene therapies. Depending on the progress of the research, Voyager could earn up to $1.5 billion in milestone payments.
-
Voyager Therapeutics’ strategy shift to gene therapy tech leads to a Pfizer alliance
The gene therapy pipeline of Voyager Therapeutics has hit several setbacks in the past year, but a strategy shift to its capsid technology is now showing promise. Pfizer has signed on as partner in a wager that Voyager’s tech holds the key to delivery of gene therapies for cardiovascular and neurological disorders.
-
Neurocrine nixes Parkinson’s gene therapy from Voyager Therapeutics alliance
The Neurocrine decision follows a clinical hold placed on the Parkinson’s program in December. It’s Voyager’s second loss of an R&D partner in the past year; AbbVie previously ended an alliance aiming to develop gene therapies for Parkinson’s and Alzheimer’s.
-
Sanofi, Voyager Therapeutics rejig gene therapy partnership
Voyager will gain worldwide rights to its Huntington’s disease therapy candidate, transfer rights to another product candidate to Neurocrine and pay Sanofi $20 million.
-
$172M in IPOs from Wave Life Sciences, Voyager Therapeutics
The biotech IPO parade marches on with two IPOs: Wave Life Sciences priced out at $102 million today, and Voyager Life Sciences raised $70 million.
-
Cambridge gene therapy startup Voyager Therapeutics raises $60M for CNS disorders
Cambridge gene therapy startup Voyager Therapeutics just wrapped up a $60 million Series B round to […]